FDA Pulls All Forms of Popular Heartburn Drug Zantac from the Market, Warns of 'Impurities'


The Food and Drug Administration announced Wednesday it is requesting that all manufacturers and sellers of a popular heartburn medication remove the drug from store shelves and halt production over potentially dangerous “impurities.”

According to an agency news release, ranitidine medication, often referred to by the common brand name Zantac, was recently discovered to contain “unacceptable levels” of a “probable human carcinogen” known as N-Nitrosodimethylamine or NDMA.

Concerned by the potentially cancerous contaminant’s presence in several over-the-counter and prescription samples of ranitidine, the FDA officially called for a total and immediate withdrawal of the drug from U.S. markets.

“The FDA is committed to ensuring that the medicines Americans take are safe and effective,” Center for Drug Evaluation and Research Director Dr. Janet Woodcock said.

“We didn’t observe unacceptable levels of NDMA in many of the samples that we tested,” Woodcock added. “However, since we don’t know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients unless its quality can be assured.”

'I Don't Know if I'm Supposed to Say This': Trump Reveals Phone Call Where He Made Unexpected Request of Hannity

The Wednesday announcement came after months of governmental and independent testing of the product.

According to the agency, initial concerns had been raised regarding potentially unhealthy levels of NDMA in ranitidine when unnamed third-party laboratories made the discovery, prompting months of further FDA investigation.

An FDA advisory regarding the potential dangers of the drug was released in November as the agency awaited further developments.

Testing results released upon closure of the investigation reportedly revealed unhealthy levels of the impurity are not present in all, or even most, samples of the drug.

Impurity levels were shown to increase with time, however, particularly when shelved samples of the drug were stored in high temperatures which may be associated with both the drug’s “distribution and handling by consumers.”

Dad and Daughter Get Payouts as School District Settles Transgender Outrage Case: 'Resounding Victory for Freedom of Speech'

Zantac and similar ranitidine antacid generics are prescribed 15 million times a year and have been for nearly a decade, USA Today reported in November.

The drug has been on the market since its approval in 1984, with expert pharmaceutical and health concerns failing to crop up until 2016.

Those taking the drug in its over-the-counter form were warned against continued use Wednesday and told to dispose of their remaining dosages. Individuals with a prescription were advised to speak to their doctors before halting usage.

“There are multiple drugs approved for the same or similar uses as ranitidine that do not carry the same risks from NDMA,” the FDA news release read, listing potential replacements like Pepcid, Tagamet, Nexium, Prevacid and Prilosec.

To date, agency testing has not revealed unhealthy levels of NDMA in any of the those alternatives.

Truth and Accuracy

Submit a Correction →

We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

, , , , , ,
Andrew J. Sciascia was the supervising editor of features at The Western Journal. Having joined up as a regular contributor of opinion in 2018, he went on to cover the Barrett confirmation and 2020 presidential election for the outlet, regularly co-hosting its video podcast, "WJ Live," as well.
Andrew J. Sciascia was the supervising editor of features at The Western Journal and regularly co-hosted the outlet's video podcast, "WJ Live."

Sciascia first joined up with The Western Journal as a regular contributor of opinion in 2018, before graduating with a degree in criminal justice and political science from the University of Massachusetts Lowell, where he served as editor-in-chief of the student newspaper and worked briefly as a political operative with the Massachusetts Republican Party.

He covered the Barrett confirmation and 2020 presidential election for The Western Journal. His work has also appeared in The Daily Caller.